Xinqiao Hospital of Chongqing: Phase 3 study in Acute Ischemic Stroke (1482 participants)
Xinqiao Hospital of Chongqing: Phase 3 study in Acute Ischemic Stroke (1482 participants). Its enrollment of 1,482 is top-decile (96th percentile of 9,177 records). Dated 42 days ago, it serves as a historical benchmark. Score 55/100. As of 2026-11-05, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 1,482 · 96th percentile of 9,177 ClinicalTrialStartPulse records · 18.5x the median
Free preview: all 14 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Xinqiao Hospital of Chongqing |
| Sponsor type | Academic and hospital |
| Study | A Multicenter, Three-Arm, Open-Label, Endpoint-Blinded Randomized Controlled Trial to Evaluate the Optimal Duration of Early Tirofiban After Intravenous Thrombolysis in Acute Ischemic Stroke |
| NCT ID | NCT07842185 |
| Phase | Phase 3 |
| Status | not yet recruiting |
| Conditions | Acute Ischemic Stroke |
| Intervention types | drug, other |
| Target enrollment | 1482 |
| Site countries | China |
| Posted | 2026-09-25 |
| Planned start | 2026-11-19 |
| Event | Newly registered study |
| Event date | 2026-09-25 |
| enrollment percentile | 96th of 9,177 (median 80, 18.5x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Xinqiao Hospital of Chongqing
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Free first: a 10-record sample of records
See the real columns before you buy. One confirmation email, nothing else unless you opt in.
Unlock Xinqiao Hospital of Chongqing + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-09-25
- Data refreshed: 2026-11-05
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Thu, 05 Nov 2026 08:46:16 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Xinqiao Hospital of Chongqing and 6,823 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,823
- Xinqiao Hospital of Chongqing's enrollment: 96th percentile of 9,177 records
- Timing: Low: older than 30 days
- Estimated pipeline if you contact every NONUS peer: $1,364,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
55 / 100 Score
- Phase 3: multi-site, larger budget.
- 1482 participants planned.
- Not yet recruiting: vendors still being chosen.
What is the ClinicalTrialStartPulse record for Xinqiao Hospital of Chongqing?
Xinqiao Hospital of Chongqing registered a Phase 3 study (NCT07842185) in Acute Ischemic Stroke targeting 1482 participants, posted 2026-09-25.
How does Xinqiao Hospital of Chongqing compare to other ClinicalTrialStartPulse records?
This is a top-decile record: its enrollment of 1,482 is 18.5x the median of 80 across 9,177 records. It is 42 days old, still within a typical 45-day follow-up window.
Xinqiao Hospital of Chongqing vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Xinqiao Hospital of Chongqing | NONUS | 1,482 | 96th | 2026-09-25 |
| Innovent Biologics (Suzhou) Co. Ltd. | NONUS | 500 | 90th | 2026-11-04 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NONUS | 420 | 88th | 2026-11-04 |
| Fujian Shengdi Pharmaceutical Co., Ltd. | NONUS | 144 | 69th | 2026-11-04 |
Related records
- NervGen Pharma
- Biogen
- Teva Branded Pharmaceutical Products R&D LLC
- Eli Lilly and Company
- Arcutis Biotherapeutics, Inc.
- Innovent Biologics (Suzhou) Co. Ltd.
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Stemline Therapeutics, Inc.
- AstraZeneca
- Teva Branded Pharmaceutical Products R&D LLC
- Genmab
ClinicalTrialStartPulse: Phase 3 ClinicalTrialStartPulse: Outside the US only
How to monitor Xinqiao Hospital of Chongqing and peer phase 3 records
Get new ClinicalTrialStartPulse records like Xinqiao Hospital of Chongqing by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.